Stockscreener 앱 받기
68.72
0.10%
-0.07
시간 외 거래:
68.95
0.23
+0.33%
Astrazeneca PLC 주식(AZN)의 최신 뉴스
AstraZeneca pledges $50bn in US investment as Trump pharma tariffs loom - Financial Times
AstraZeneca says to invest $50 bn in the US - Yahoo.co
AstraZeneca To Invest $50 Bln In U.S. By 2030 To Boost Medicine Production And Research - Nasdaq
AstraZeneca grows US presence with $50B in spending plans - BioPharma Dive
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
AstraZeneca to invest $50B in US by 2030 - breakingthenews.net
AstraZeneca picks Virginia for multibillion-dollar manufacturing site - Richmond Times-Dispatch
AstraZeneca Vows to Spend $50 Billion on US Manufacturing, Development - Bloomberg
AstraZeneca to spend $50-billion to expand manufacturing, research capabilities in U.S. - The Globe and Mail
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - Yahoo Finance
What analysts say about AstraZeneca PLC Depositary Receipt stockPowerful profit generation - Autocar Professional
AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer - Benzinga
AstraZeneca to invest $50B in US economy by 2030 - AOL.com
AstraZeneca’s Observational SLE Study in Kazakhstan: Key Insights for Investors - TipRanks
AstraZeneca Plans Massive $50B US Investment: New Virginia Mega-Factory to Create Thousands of Jobs - Stock Titan
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms - MarketScreener
AstraZeneca’s Promising Pediatric SLE Study: Anifrolumab’s Potential Impact - TipRanks
AstraZeneca’s New Phase II Study: A Potential Breakthrough in Liver Cancer Treatment - TipRanks
AstraZeneca’s COPD Study: Potential Game-Changer for Cardiopulmonary Outcomes - TipRanks
AstraZeneca’s AIRSUPRA Study: A Potential Game-Changer in Asthma Treatment - TipRanks
AstraZeneca reports positive results from Tagrisso combo trial - Seeking Alpha
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters - Stocktwits
AstraZeneca’s lung cancer drug shows improved survival with chemotherapy combo - Investing.com UK
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Is it worth me buying more AstraZeneca shares at just over £13? - Yahoo.co
What drives AstraZeneca PLC Depositary Receipt stock priceBreakthrough profit margins - PrintWeekIndia
Is AstraZeneca PLC Depositary Receipt a good long term investmentUnrivaled growth potential - jammulinksnews.com
AstraZeneca PLC Depositary Receipt Stock Analysis and ForecastHigh-performance investment picks - Autocar Professional
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors? - Yahoo Finance
AstraZeneca’s Latest Study on Dato-DXd for NSCLC: Key Insights for Investors - TipRanks
AstraZeneca’s CASPIAN Study: A Promising Update in Lung Cancer Treatment - TipRanks
AstraZeneca’s Promising NSCLC Study: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s PRIMULA Lac Study: A Key Step in Anifrolumab’s Market Journey - TipRanks
AstraZeneca’s AZD5004 Study: A New Hope for Type 2 Diabetes Treatment? - TipRanks
AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for Lupus - The Globe and Mail
AstraZeneca’s Phase III Trial: A Potential Game Changer in Breast Cancer Treatment - TipRanks
AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Game-Changer - TipRanks
AstraZeneca’s Real-World Study on Olaparib for Prostate Cancer: Key Insights for Investors - The Globe and Mail
AstraZeneca’s AQUALIS Study: Enhancing CLL Patient Quality of Life with Acalabrutinib - TipRanks
AstraZeneca’s DESTINY-Endometrial01 Study: A New Hope for Endometrial Cancer Treatment - TipRanks
AstraZeneca’s REBECCA Study: Real-World Insights into Early Breast Cancer Management - TipRanks
AstraZeneca’s Moxetumomab Pasudotox Safety Study Terminated: Market Implications - TipRanks
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies - MSN
AstraZeneca’s Promising Study on Endometrial Cancer Treatment - TipRanks
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
Contact Levi & Korsinsky by February 21, 2025 Deadline to Join Class Action Against AstraZeneca PLC(AZN) - MarketScreener
AstraZeneca’s New Study Sheds Light on COPD Burden in Egypt - TipRanks
AstraZeneca and Bayer’s Collaborative Study on Metastatic Prostate Cancer: A Potential Game-Changer? - TipRanks
AstraZeneca’s DAISY Study: A New Hope for Systemic Sclerosis Treatment - TipRanks
AstraZeneca’s OPTIMISE-CKD Study: A Closer Look at Chronic Kidney Disease Management in Spain - TipRanks
AstraZeneca’s Real-Life Study on Benralizumab: Market Implications and Progress - The Globe and Mail
AstraZeneca’s AI-Driven Breast Cancer Risk Study: A New Frontier in Personalized Medicine - TipRanks
AstraZeneca’s Dapagliflozin Study: A New Hope for Chronic Kidney Disease in China - TipRanks
AstraZeneca’s New Phase III Study: A Potential Game-Changer in Biliary Tract Cancer Treatment - TipRanks
자본화:
|
볼륨(24시간):